Gb Sciences Stock Performance
| GBLX Stock | USD 0.0003 0 88.00% |
GB Sciences holds a performance score of 6 on a scale of zero to a hundred. The firm owns a Beta (Systematic Risk) of -53.79, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning GB Sciences are expected to decrease by larger amounts. On the other hand, during market turmoil, GB Sciences is expected to outperform it. Use GB Sciences information ratio and the relationship between the value at risk and period momentum indicator , to analyze future returns on GB Sciences.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in GB Sciences are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile essential indicators, GB Sciences showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1.1 M | |
| Total Cashflows From Investing Activities | 1.5 M |
GBLX |
GB Sciences Relative Risk vs. Return Landscape
If you would invest 0.59 in GB Sciences on December 4, 2024 and sell it today you would lose (0.56) from holding GB Sciences or give up 94.92% of portfolio value over 90 days. GB Sciences is currently generating 4.433% in daily expected returns and assumes 56.2141% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than GBLX, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
GB Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GB Sciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as GB Sciences, and traders can use it to determine the average amount a GB Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0789
| Best Portfolio | Best Equity | GBLX | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 56.21 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.43 actual daily | 88 88% of assets have lower returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average GB Sciences is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GB Sciences by adding it to a well-diversified portfolio.
GB Sciences Fundamentals Growth
GBLX Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of GB Sciences, and GB Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GBLX Pink Sheet performance.
| Return On Equity | -50.98 | |||
| Return On Asset | -0.21 | |||
| Current Valuation | 10.19 M | |||
| Shares Outstanding | 379.21 M | |||
| Price To Earning | 4.04 X | |||
| Price To Book | 1.08 X | |||
| Price To Sales | 1.91 X | |||
| EBITDA | 398.73 K | |||
| Cash And Equivalents | 53.96 K | |||
| Total Debt | 397.31 K | |||
| Debt To Equity | 1.07 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.87 M) | |||
| Total Asset | 2.55 M | |||
| Retained Earnings | (78.28 M) | |||
| Current Asset | 2.2 M | |||
| Current Liabilities | 1.32 M | |||
About GB Sciences Performance
Evaluating GB Sciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if GB Sciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GB Sciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada. Growblox Sciences operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.Things to note about GB Sciences performance evaluation
Checking the ongoing alerts about GB Sciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for GB Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GB Sciences is way too risky over 90 days horizon | |
| GB Sciences has some characteristics of a very speculative penny stock | |
| GB Sciences appears to be risky and price may revert if volatility continues | |
| GB Sciences has a very high chance of going through financial distress in the upcoming years | |
| GB Sciences currently holds 397.31 K in liabilities with Debt to Equity (D/E) ratio of 1.07, which is about average as compared to similar companies. GB Sciences has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist GB Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, GB Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GB Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GBLX to invest in growth at high rates of return. When we think about GB Sciences' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (530.87 K) with loss before overhead, payroll, taxes, and interest of (881.46 K). | |
| GB Sciences currently holds about 53.96 K in cash with (1.87 M) of positive cash flow from operations. | |
| Roughly 13.0% of GB Sciences shares are held by company insiders |
- Analyzing GB Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GB Sciences' stock is overvalued or undervalued compared to its peers.
- Examining GB Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GB Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of GB Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GB Sciences' pink sheet. These opinions can provide insight into GB Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GBLX Pink Sheet Analysis
When running GB Sciences' price analysis, check to measure GB Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GB Sciences is operating at the current time. Most of GB Sciences' value examination focuses on studying past and present price action to predict the probability of GB Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GB Sciences' price. Additionally, you may evaluate how the addition of GB Sciences to your portfolios can decrease your overall portfolio volatility.